Background Compared to non-inflammatory breast cancer (non-IBC), inflammatory breast cancer (IBC) has less favorable survival and is more likely to be estrogen receptor (ER) and progesterone receptor (PR) negative. ER-/PR-tumors, regardless of histology, have less favorable survival. While black women are more likely to have IBC and ER-/PR-tumors than white women, it is unclear whether the racial disparity in survival is explained by these factors. The objective of this study was to assess racial/ethnic differences in breast cancer survival by inflammatory status and hormone receptor status.
Conclusion Compared to NHW women, black women had poorer survival regardless of inflammatory status and hormone receptor status and API women had better survival. These results suggest that factors other than inflammatory status and hormone receptor status may play a role in racial/ethnic disparities in breast cancer survival. 
Background
It is well known that black patients have significantly shorter survival from breast cancer compared to white patients [1] . Part of the racial disparity may be related to racial differences in inflammatory status and hormone receptor status of the disease. Inflammatory breast cancer (IBC) is an uncommon type of breast cancer that is notably more aggressive and has less favorable survival outcomes compared to non-inflammatory breast cancer (non-IBC).
Patients with IBC have a 43 % higher rate of death than those with non-IBC after adjusting for factors related to prognosis [2] . While it is known that overall breast cancer mortality rates for black women are 39 % greater than that for white women [1] , studies showed that black women are more likely to be diagnosed with IBC compared to white women [3] . Nevertheless, within IBC, black women had a shorter median survival time (20 months) than their white counterparts (32 months) [3, 4] . Hormone receptor status (estrogen receptor, ER, and progesterone receptor, PR) is well known to be an independent predictor of breast cancer survival [5] [6] [7] [8] [9] : Breast cancer patients with hormone-receptor-negative tumors have increased mortality and shorter survival compared to those with hormone receptor positive tumors. It is well known that black women are nearly twice as likely to have ER-and PR-negative tumors compared to white women [5, [10] [11] [12] . While the higher rates of hormone-receptor-negative tumors among black women may account for some of the black-white disparity in survival [5] , other factors must also be important because this disparity persists after accounting for hormone receptor status [13] .
Inflammatory status and hormone receptor status of breast cancer may be related. IBC patients are more likely to have ER-/PR-negative tumors [11, 14] . In addition, IBC survival may be worse if tumors are also hormone receptor negative [14] . Because black patients are more likely to have both IBC and ER-/PR-tumors than white patients, it would be important to know whether the black/white difference in IBC survival is explained at least partially by more ER-/PR-tumors among blacks and whether the black/white disparity in IBC survival is greater among patients with tumors that are also ER-and PR-. To the best of our knowledge, there have been no studies that have assessed black/white differences in breast cancer survival by both inflammatory status and hormone receptor status of the disease. Furthermore, no other racial/ethnic groups have been compared with non-Hispanic whites (NHWs) for breast cancer survival by both inflammatory status and hormone receptor status. The objective of this study was to assess whether blacks, NHWs, Hispanic whites (HWs), and Asian/Pacific Islanders (APIs) differ in breast cancer survival by both inflammatory status and hormone receptor status using the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) data.
Methods

Data source and study subjects
This study was based on the National Cancer Institute's SEER database for public use that consists of eighteen population-based registries (SEER-18, November 2011 Submission) [15] [15] , which represent approximately 28 % of the US population [16] . Since the Alaska Native Registry only collects data on American Indian and Alaska Native populations, it was excluded from the study.
The subjects of this study were women aged 18 or older who were histologically diagnosed with breast cancer. Data on ER and PR became available in 1990; therefore, only patients diagnosed from 1990 to 2009 were included. Racial/ethnic groups included in the study were NHWs, HWs, blacks, and APIs. All black and API women were eligible for inclusion regardless of ethnicity. Other races were excluded due to insufficient sample size. As IBC is always diagnosed at least as stage IIIB breast cancer due to involvement of the dermal lymphatics [17] , only women with American Joint Committee on Cancer (AJCC) stages IIIB, IIIC, or IV were included.
Study variables
The study subjects were classified by whether their cancer was inflammatory or non-inflammatory, as well as by hormone receptor status. IBC cases were defined using the comprehensive case definition which includes histologic type ICD-O-3 equaling to '8530' [18] , historic extent of disease equaling to 70 for years 1990-2003, or derived AJCC extent of the tumor (T, 6th edition) equaling to 'T4d' and collaborative staging extension being between 71 and 73 for years 2004 and later [19] [20] [21] . Hormone receptors included ER and PR. The positive and negative states of ER or PR were determined by tumor specimen assay results prior to receipt of neoadjuvant systemic therapy (if available) or after systemic treatment (otherwise). If any sample was recorded as receptor positive, then the receptor was documented as positive [22] . Based on the states of ER and PR, there were three mutually exclusive hormone receptor groups. Tumors that were positive for both estrogen and PRs were categorized as hormone receptor positive (ER?/PR?), and tumors that were negative for both receptors were grouped as hormone receptor negative (ER-/PR-). If estrogen or PR states did not coincide, hormonal status was defined as being mixed (ER?/PR-or ER-/PR?). Cases not belonging to any of the three ER/PR groups were excluded from the analysis.
Vital status was determined as of 31 December 2009. Cause of death was obtained from the SEER cause-specific death classification, which is supplied by cancer registries based on the underlying cause of death from death certificates. The outcome for this study was death of breast cancer. Women who died of causes other than breast cancer were censored.
Statistical analyses
We first described the distribution of demographic, pathologic, and tumor characteristics by race/ethnicity and inflammatory status. We then conducted survival analysis. Breast cancer-specific survival time in years was defined as time from diagnosis date until death date, last contact date, or study cutoff date (31 December 2009) if still alive.
We used the Kaplan-Meier method to estimate breast cancer-specific survival time by race/ethnicity and the logrank statistic to evaluate whether there were statistical differences between racial/ethnic groups within each subgroup defined by inflammatory status or/and hormone receptor status.
For each of the subgroups stratified by inflammatory status or/and hormone receptor status, the Cox proportional hazard regression analysis was used to assess racial/ethnic differences while adjusting for potential confounders including age at diagnosis, marital status, stage, grade, surgery, and radiation. The hazard ratios (HRs) and their 95 % confidence intervals (CIs) were calculated. To evaluate whether racial/ethnic differences might vary by menopausal status of the patients, we further conducted Cox analysis stratified by age (\50 vs. C50 years, a surrogate of menopausal status). The assumptions of the proportional hazards model were confirmed by visual assessment of the residuals. A two-sided p value of B0.05 was used to determine statistical significance. SAS 9.3 (SAS Institute, Inc., Cary, NC) was utilized for all analyses.
Results
The study subjects were 30,258 NHW, 6,448 black, 4,183 HW, and 2,691 API female breast cancer patients, including 7,748 (18 %) diagnosed with IBC and 35,832 (82 %) with non-IBC (Table 1) . For both IBC and non-IBC, HWs, APIs, and blacks tended to be younger compared to NHWs. Compared to other racial/ethnic groups, black patients were less likely to be married and undergo surgery and radiation treatment for both IBC and non-IBC. Inflammatory breast tumors were more likely to be ER-/ PR-for all racial/ethnic groups. Despite inflammatory status, blacks were more likely to have ER-/PR-tumors than women in the other racial/ethnic groups. NHWs tended to be less likely to have stage IV IBC or grade III/IV non-IBC than minority groups.
The log-rank statistic showed that there were racial/ ethnic differences for each of the Kaplan-Meier curves by hormone receptor and inflammatory status (see Figs. 1, 2) . Specifically, for all of the subgroup comparisons, black women tended to have shorter survival than women in other racial/ethnic groups despite inflammatory status or hormone receptor status. A similar racial difference was observed when data were stratified by both inflammatory status and hormone receptor status (data not shown). API women tended to have the longest survival, except for IBC Cancer Causes Control (2014) 25:959-968 961 as a whole or IBC with ER/PR both being negative or positive. Table 2 shows the HRs of minority groups compared to NHWs adjusted for potential confounders. Blacks tended to have significantly increased hazard compared to NHWs despite inflammatory status or/and hormone receptor status. The adjusted HRs were 1.32 (95 % CI 1.21-1.44), 1.43 (95 % CI 1.20-1.69), and 1.30 (95 % CI 1.16-1.47) for IBC, IBC with ER?/PR?, and IBC with ER-/PR-, respectively. The HRs were similar for non-IBC, non-IBC with ER?/PR?, and non-IBC with ER-/PR-. When ER/ PR states were mixed, the results remain similar (data not shown). API women tended to have a lower hazard than NHWs for all ER/PR states and most combinations of ER/ PR and inflammatory states. While the HRs tended to be slightly lower than one for HWs compared to NHWs, the differences were never statistically significant. Table 3 shows the adjusted HRs stratified by age at diagnosis. The results among patients aged 50 or older were similar to those in Table 2 except that the HR became no longer significant for APIs with IBC as a whole. Among patients aged younger than 50 years, the HRs for blacks compared to NHWs were higher than the corresponding estimates in the older group for ER?/PR? or non-IBC with ER?/PR?. The same tendency was observed for non-IBC and IBC with ER?/PR?. For APIs, the HRs were no longer significantly lower in the younger group. The HRs for younger HWs compared to NHWs were similar to those from the older group. Racial differences in the strata with mixed ER/PR states tended to be similar (data not shown).
Discussion
Black women had significantly worse survival compared to NHW women regardless of inflammatory status, hormone receptor status, and age-group in our study of stage III and IV breast cancer. Conversely, API women tended to have the better breast cancer survival compared to NHW women, despite inflammatory status or ER/PR status. The better survival among API women was observed for most groups defined by a combination of inflammatory and ER/ PR states. HW and NHW women tended to have similar survival regardless of inflammatory and ER/PR states. In general, we found that racial/ethnic differences in breast cancer survival might be similar despite inflammatory status and hormone receptor status. Racial/ethnic differences in survival may relate to various factors such as accessibility to medical care, use of medical care, and tumor pathologic and biological features. Our study found similar racial/ethnic differences regardless of tumor characteristics (hormone receptor status and inflammatory status). This is consistent with some previous studies, which also suggested similar racial/ethnic difference for breast cancer with various pathologic features [23, 24] . These research results imply that factors other than these tumor features may play a large role in racial/ethnic disparities in breast cancer survival.
Use of medical care may be a major factor explaining the identified racial/ethnic disparities. It has been documented that, on average, blacks have a lower level of access to health care compared to whites [25] . Therefore, they are less likely to have timely diagnosis and treatment, receive standard treatment, and complete follow-up surveillance and care than white patients [26] [27] [28] [29] . It is also well demonstrated that black patients were more likely to present with clinically detected cancers rather than screendetected cancer and have delayed diagnoses compared to white patients [26] . Many, but not all [30] [31] [32] , studies found that black patients are more likely to have delayed treatment [26, 29, 33, 34] and are less likely to receive definitive primary therapy and adjuvant chemotherapy [34] [35] [36] [37] [38] , hormonal therapy [30] , radiation after lumpectomy [29, 39, 40] , or mastectomy [41] than their white counterparts. While research on racial disparity in follow-up care has been sparse, it has been suggested that black patients may receive less medical monitoring or follow-up care [28] . As a result of the racial disparities in diagnosis, treatment, and follow-up care, black patients may have worse survival than whites across different breast cancer types including inflammatory status and ER/PR status. Our study also showed that the racial difference in survival appeared larger for patients younger than 50 years than those older among the patients with ER?/PR?. A similar result was observed previously in a study that suggested that Medicare availability for older women might help reduce racial differences in cancer care [42] .
We do not exclude the possibility that biological features other than inflammatory status and hormone receptor status may be related to the racial/ethnic differences in survival. For example, black patients may be more likely to have SEER 18, 1990 SEER 18, -2009 tumors with negative status of human epidermal growth factor-like receptor 2 (HER2) [43, 44] or P53 mutation [45] , which are related to survival [43, [46] [47] [48] . Although inconsistent [43, 47, 48] , some studies on triple-negative breast cancer, which included HER2-in addition to ER-/PR-, have found no racial differences in survival [49] [50] [51] , suggesting a minimal potential impact of HER2 on racial differences. Therefore, there is a possibility that biomarkers of breast cancer other than inflammatory status and ER/PR status may be associated with racial/ethnic disparities in survival in addition to the access to and use of medical care. Our finding of better survival among API women than whites is consistent with previous studies [52, 53] . Similar to our study, an earlier SEER-based study found that, after adjusting for potential confounding variables, Asians experience significantly better survival compared to NHWs regardless of ER/PR status [13] . It is largely unclear what factors may account for the survival differences between APIs and other racial/ethnic groups because data on Asians have been limited and research results have been inconsistent. Some studies have shown that Asian women were more likely to adhere to adjuvant hormonal therapy [54] or have follow-up mammography [55] than white women. However, other studies found no differences between Asian and white women in the receipt of adjuvant radiation treatment after breast-conserving surgery (BCS) [56] , but Asian women were less likely to undergo BCS than whites [57] . Therefore, research is warranted on the role of medical care and other factors on survival differences between Asians and other racial/ethnic groups. While the large dataset from the SEER registries makes it possible to assess racial/ethnic differences in survival by IBC inflammatory breast cancer, NH non-Hispanic, API Asian/Pacific Islander both inflammatory status and ER/PR status, the limitations of this study should be kept in mind. The study was based on the existing data from the cancer registries; therefore, the effects of confounding factors that are not contained in the dataset cannot be excluded. For example, information on cancer treatment is not complete and detailed in the SEER data, precluding us from having solid assessment of and control for its potential effects on the results. Lack of individuallevel information on socioeconomic status, which is related to breast cancer survival and correlated with racial/ethnic background [58] , prevented us from controlling for its impacts in the analyses. This analysis was limited to cancer stages III and IV based on the definition of IBC. Thus, the results on ER/PR reflect only those for these tumor stages rather than all stages including stages I and II.
In conclusion, our study found that racial/ethnic disparities in breast cancer survival persist despite inflammatory status and hormone receptor status. These results imply that factors other than inflammatory status and hormone receptor status, such as access to or use of medical care, and/or other biomarkers, may play a role in racial/ ethnic disparities in breast cancer survival.
